Onori et al. [57] had reported that the secretin inhibits the cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of the secretin receptor, and the modulation of SCTR expression might behave as a tool to treat cholangiocarcinoma. Here, SCT is linked to cholangiocarcinoma.